ESPR common stock will cease trading on Nasdaq; holders should expect to receive $3.16 per share in cash plus one CVR per share. The CVRs are non-transferable and contingent on achieving sales milestones for NEXLETOL/NEXLIZET (2027) and ENBUMYST (through 2030). Monitor future announcements regarding milestone achievement for potential CVR value realization.
Price Chart
Executive Summary
Esperion Therapeutics completed its acquisition by ArchiMed (via Essence Parent Inc.) on July 13, 2026, for $3.16 per share in cash plus one contingent value right (CVR) per share, representing up to $100M in aggregate milestone payments. The merger triggers delisting from Nasdaq, a change of control, replacement of the board, and termination of the prior credit agreement with new debt financing from BioPharma Credit.
Key Financial Metrics
Key Facts
- Merger completed on July 13, 2026; each share converted into $3.16 cash plus one CVR
- Total cash consideration approximately $1.1 billion, funded by equity and debt from BioPharma Credit
- CVRs entitle holders to up to $100M aggregate contingent payments tied to U.S. net sales milestones for NEXLETOL/NEXLIZET (bempedoic acid) and ENBUMYST (bumetanide)
- Common stock to be delisted from Nasdaq; Form 15 to be filed to suspend SEC reporting obligations
- All prior directors resigned; Justin Bateman and Ankit Pareek appointed as new directors
- Prior credit agreement with GLAS USA LLC terminated and repaid in full
- New loan agreement entered with BioPharma Credit PLC and affiliates
Financial Impact
Cash consideration of approximately $1.1 billion plus CVRs with up to $100M in aggregate milestone payments
Risk Factors
- CVR milestones may not be achieved, resulting in no additional payments
- No further liquidity for common stock after delisting
- CVRs are non-transferable and cannot be traded
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-082926 |
| Document: tm2620034d3_ex3-2.htm | 0001104659-26-082926 |
| Document: tm2620034d3_8k.htm | 0001104659-26-082926 |
| Document: tm2620034d3_ex4-1.htm | 0001104659-26-082926 |
| Document: tm2620034d3_ex3-1.htm | 0001104659-26-082926 |
| Document: 0001104659-26-082926-index-headers.html | 0001104659-26-082926 |
| Document: 0001104659-26-082926-index.html | 0001104659-26-082926 |
| Document: 0001104659-26-082926.txt | 0001104659-26-082926 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 3, 2026 29d ago | Court Ruling | โ | awaiting T+5 | โ | โ |
Aug 13, 2026 7w ago | Institutional Cluster | โ | awaiting T+5 | โ | โ |
Jul 23, 2026 10w ago | 15-12G | โ | awaiting T+5 | โ | โ |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | โ | โ |
Jul 16, 2026 11w ago | EFFECT | $3.18 awaiting T+5 | awaiting T+5 | โ | โ |
Jul 13, 2026 11w ago | 25-NSE | $3.19 awaiting T+5 | awaiting T+5 | โ | โ |
Jul 13, 2026 11w ago | 8-K | $3.19 awaiting T+5 | awaiting T+5 | โ | โ |
Jun 16, 2026 15w ago | DEFA14A | $3.17 $3.15 | โผ โ0.63% | โฒ +0.41% | โ |
Jun 11, 2026 16w ago | Institutional Cluster | $3.15 $3.17 | โฒ +0.63% | โฒ +0.20% | โ |
Jun 9, 2026 16w ago | 8-K | $3.14 $3.16 | โฒ +0.64% | โผ โ2.80% | โ |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access